| Medical Nicotine Transdermal Skin Patch Market Outlook: Opportunities & Trends |
|
| According to a newly published market research report by 24LifeSciences, the global medical nicotine transdermal skin patch market was valued at USD 1.45 billion in 2025 and is projected to reach USD 2.87 billion by 2034, growing at a compound annual |
| read more |
|
|
| What Is the Future of Glaucoma Therapeutics Market ? 2026–2034 Outlook |
|
| According to a newly published market research report by 24LifeSciences, global glaucoma therapeutics market was valued at USD 5,868 million in 2024 and is projected to reach USD 8,355 million by 2031, growing at a compound annual growth rate (CAGR) |
| read more |
|
|
| 11-Beta-Hydroxysteroid Dehydrogenase Type 2 (HSD11B2) Antibody Market Outlook |
|
| According to a newly published market research report by 24LifeSciences, 11-Beta-Hydroxysteroid Dehydrogenase Type 2 (HSD11B2) Antibody Market was valued at USD 56.8 million in 2025 and is projected to reach USD 92.4 million by 2034, growing at a com |
| read more |
|
|
| What Is the Future of Rheumatoid Arthritis (RA) Medications Market ? 2026–2034 Outlook |
|
| According to a newly published market research report by 24LifeSciences, Global Rheumatoid Arthritis (RA) Medications Market was valued at USD 26.5 billion in 2025 and is projected to reach USD 39.8 billion by 2034, growing at a compound annual growt |
| read more |
|
|
| Soft Tissue Core Biopsy Market Size & Share Analysis 2032 |
|
| According to a newly published market research report by 24LifeSciences, global soft tissue core biopsy market was valued at USD 1.5 billion in 2024 and is projected to reach USD 2.45 billion by 2032, growing at a compound annual growth rate (CA |
| read more |
|
|
| Dextran Biodegradable Bead Market Set to Hit USD 528.7 Million by 2034 at 6.3% CAGR |
|
| Global Dextran (Leuconostoc) as Biodegradable Bead for Column Chromatography market size was valued at USD 285.4 million in 2025. The market is projected to grow from USD 304.6 million in 2026 to USD 528.7 million by 2034, exhibiting a CAGR of 6.3% d |
| read more |
|
|
